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METHODS FOR INCREASING LEPTIN 
LEVELS USING NICOTINIC ACID 
COMPOUNDS 
RELATED APPLICATION 
This application claims priority of provisional application 
No. 60/274,349, ?led Mar. 8, 2001, incorporated by refer 
ence. 
FIELD OF THE INVENTION 
The invention relates to the use of niacin derivatives and 
niacin in the regulation of leptin modulated pathWays. 
Speci?cally, niacin and its derivatives, such as nicotinate 
esters, lauryl nicotinate ester in particular, stimulate produc 
tion of leptin, With rami?cations as discussed infra. 
BACKGROUND AND PRIOR ART 
Leptin, a 167 amino acid protein encoded by the ob gene, 
Was identi?ed in the course of research in identifying 
molecular defects in an obesity prone strain, i.e., the “ob/ob” 
mouse. It has been found that leptin is produced for the most 
part in White adipose tissue, With very small amounts being 
found in broWn adipose tissue. Exemplary of the patent 
literature relating to this molecule are US. Pat. Nos. 6,132, 
724; 6,124,448; 6,124,439; 6,068,976; 6,048,837 and 5,795, 
909, all of Which are incorporated by reference. 
The ?rst reports on leptin suggested that it Was an 
adipocyte derived, signaling molecule, Which limited food 
intake and increased energy expenditure, i.e., an “adiposat.” 
The evidence supporting this included observed decreases in 
body Weight, and improved metabolic control in rodents that 
evidenced genetic or diet induced obesity that Were injected 
With leptin. In the case of ob/ob mice, Which have mutations 
in the ob gene, leading to synthesis of defective leptin 
molecules that are degraded intracellularly, the effect of 
leptin is especially pronounced. The ob/ob mice are obese, 
diabetic and sterile, and exhibit reduced activity, 
metabolism, and body temperature. In addition, leptin 
de?cient ob/ob mice suffer from seriously delayed Wound 
healing. Systemic or topically administered leptin has been 
shoWn to improve re-epitheliaZation of Wounds in this 
model. See Frank, et al., J. Clin. Invest. 106: 501—509 
(2000). As such, the ob/ob mouse has been used as a model 
system for testing drugs for their ability to reverse impaired 
Wound healing. 
In addition to the effect on leptin de?cient mice, discussed 
supra, leptin markedly promoted re-epitheliaZation in Wild 
type mice. In addition, STAT 3 and peroxisome-proliferator 
activated receptor (“PPAR” hereafter), Which are the doWn 
stream regulators in the leptin pathWay, are involved in skin 
homeostasis. See Komuvres, et al., J Invest. Dermatol 
115:361—267 (2000). STAT 3 has been shoWn to play an 
essential role in skin remodeling, including hair follicle 
cycling and Wound healing. It is also knoWn that PPARO. 
activators normaliZe cell proliferation, including epidermal 
differentiation, and accelerate the development of the epi 
dermal permeability barrier. See Hanley, et al., J. Clin Inv. 
100:705—712 (1997). Recently, it has been demonstrated that 
PPARO. activators inhibit murine skin tumor promotion. This 
is consistent With PPARO. having a role in skin physiology. 
See Thuillier, et al., Mol. Carcinogenesis 29:134—142 
(2000). 
Further research on leptin has revealed that the molecule 
alters the transcription of several adipose speci?c genes 
involved in lipogenesis, lipolysis, and energy metabolism. It 
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also appears to trigger apoptosis in White adipose tissue. 
Most of the molecule’s metabolic effects appear to result 
from speci?c interactions With receptors located in the 
central nervous system, and in peripheral tissues. The recep 
tor has been identi?ed and is a Class I cytokine receptor that 
belongs to a family that includes the IL-2 receptor, interferon 
receptor and groWth hormone receptor. In brief, the leptin 
receptor transmits leptin signal to the three STAT molecules 
STAT 3, 5, and 6, referred to collectively as the “fat 
STATS.” 
The accepted vieW of leptin is that its primary role is to 
prevent obesity via regulating food intake and thermogen 
esis via action on hypothalomic centers. Recent evidence 
suggests, hoWever, that leptin may have an additional role, 
i.e., it may exhibit antisteatotic activity, in that fatty acid 
over-accumulation in non-adipose tissue may be prevented 
by leptin mediated regulation of [3-oxidation. Leptin 
increases enZymes involved in fatty acid oxidation and 
stimulates a previously unobserved form of lipolysis, Where 
glycerol is released Without proportional release of free fatty 
acids. 
Various leptin receptor isoforms are expressed throughout 
the body suggesting that leptin has additional physiological 
functions on extra-neural tissue. Studies have been carried 
out to evaluate tissue responsiveness to leptin, via determin 
ing What effects, if any, it has on glucidic and lipidic 
metabolism, as Well as expression of some enZymes. If a 
direct effect of leptin on a given tissue is observed, it implies 
rapid induction of signal transduction mechanisms, ?oWing 
from hormone/receptor binding. Essentially the mechanism 
of action can be summariZed as folloWs: leptin activates 
STAT 3 in adipose tissue, binding of leptin to its receptor 
leads to receptor oligomeriZation, and JAK activation, lead 
ing in turn to STAT phosphorylation; phosphorylated STATS 
dimeriZe and translocate into nuclei, Where they activate 
target genes. In brief: 
(i) Leptin activates STAT 3, and increases PPARO. activ 
ity; 
(ii) PPARot/PPRE induces apo A-I expression in liver 
cells; 
(iii) STAT 3/PPARO. is essential for skin homeostasis; 
(iv) PPARO. activators inhibit mouse skin tumor promo 
tion. 
See, eg Bendinelli, et al., Mol. Cell Endocrin 168:11—20 
(2000); Unger, et al., Proc. Natl. Acad. Sci USA 
96:2327—2332 (1992); Peters, et al., J. Biol. Chem. 
272:27307—27312 (1997); Hanley, et al., J. Clin. Invest. 
100:705—712 (1997); Sano, et al., EMBOJ 18:4657—4666 
(1999); Thuillier, et al., Mol. Carcin 29:134—142 (2000). 
In addition to playing a role in energy regulation, leptin 
also regulates endocrine and immune functions. Leptin 
levels increase acutely during infection and in?ammation, 
and may represent a protective component of the host 
response to in?ammation. Leptin de?ciency increases sus 
ceptibility to infectious and in?ammatory stimuli and is 
associated With dysregulation of cytokine production. See 
Faggioni, et al., FASEB J. 15:2565—2571 (2001). 
In addition, it can be hypothesiZed that the pathWay 
described supra can also lead to skin homeostasis and 
remodeling, Which in turn leads to epidermal barrier 
development, Wound healing, and hair groWth, as Well as the 
inhibition of skin tumor promotion caused by increased 
immune functions. This is summariZed in FIG. 1. 
Niacin is essential to formation of the coenZymes nicoti 
namide dinucleotide (NAD), and NAD phosphate (NADP), 
Where the nicotinamide moiety acts as an electron acceptor 
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or hydrogen donor in many biological redox reactions. To 
elaborate, NAD functions as an electron carrier for intrac 
ellular respiration, and as a coenZyme in the oxidation of 
fuel molecules. NADP acts as a hydrogen donor in reductive 
biosynthesis, including fatty acid and steroid synthesis. As is 
the case With NAD, it also acts as a coenZyme. 
NAD is the substrate for three classes of enZymes that 
transfer ADP-ribose units to proteins involved in DNA 
repair, cell differentiation, and cellular calcium mobiliZation. 
Nicotinic acid, in contrast to nicotinamide, When given in 
doses of 1.5—4 g/day improves blood cholesterol pro?les. 
Acipimox, a commercially available, nicotinic acid ana 
log and hypolipodemic agent, Was shoWn to increase plasma 
leptin levels in transgenic mice. See, e.g., Worm, et al., Eur. 
J. Endocrin 143:389—395 (2000). 
It has been shoWn that nicotinic acid derivatives have 
ef?cacy in, inter alia, skin cell protection, DNA repair, etc. 
See, e.g., US. Pat. No. 6,337,065, ?led Dec. 1, 1999 to 
Jacobson, et al., incorporated by reference in its entirety. 
This application describes various nicotinic acid derivatives, 
including a dodecyl, or lauryl nicotinic acid ester. It has noW 
been found that such nicotinic acid esters, such as lauryl 
nicotinic acid ester, stimulate leptin production to an extent 
not seen With niacin. As the nicotinic acid esters can be 
formulated as e.g., materials suitable for topical application, 
a neW approach to leptin stimulation and production is 
provided. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 is a proposed mechanism and effect pathWay 
believed to operate in the invention. Note a ?at line means 
the target condition is inhibited. Hence, the effect of leptin 
on skin tumor promotion is inhibition of the tumor. 
FIG. 2 summariZes data relating to leptin production in 
adipocytes in vitro. 
FIG. 3 compares the result of experiments designed to 
determine the levels of plasma leptin in test animals, after 
niacin Was administered in the form of lauryl nicotinic acid 
ester. 
FIG. 4 presents a summary of data generated folloWing 
the Work of example 2, in Which serum leptin levels Were 
measured. “NIA 114” is the lauryl ester, While “NIA 112” is 
the myristyl ester. 
FIG. 5 summariZes results of experiments designed to 
shoW changes in Wound siZe folloWing administration of the 
nicotinic acid esters. 
FIG. 6 sets forth parallel results, in Which the serum leptin 
levels of the mice Were measured. 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
EXAMPLE 1 
Adipose tissue is recogniZed as the major source of leptin 
production in animals. As such, experiments Were designed 
to determine the effect of niacin on leptin production in 
adipocytes. 
Human adipocytes Were obtained in accordance With 
standard methods. In brief, preadipocytes Were collected 
from subcutaneous adipose tissue, folloWing collagenase 
treatment. The preadipocytes Were plated, and alloWed to 
differentiate for 3 Weeks, to form adipocytes. 
The adipocytes Were then incubated, in 0.6 ml of DMEM/ 
F-10 medium, to Which 2% bovine serum albumin Was 
added. In addition, cultures either received 0.1 mM niacin, 
or did not. 
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After 24 hours, the culture medium Was analyZed for 
leptin, using a commercially available ELISA kit. 
The results, Which are presented in FIG. 2, shoW that in 
the cultures to Which niacin Was added, leptin production 
increased 62%. 
EXAMPLE 2 
Female apoB/CETP double transgenic mice, obtained 
from a commercial supplier, Were divided into 3 groups, and 
housed as six animals per cage. One group served as control, 
and received a standard diet, Without added niacin. Backs 
Were shaved, and lotion Was applied Which Was identical to 
the lotion applied to the third group, as described infra, 
Without lauryl nicotinate ester. A second group received 
niacin, in the form of its sodium salt, dissolved in drinking 
Water at a concentration of 0.75% (0.63% free acid). The 
niacin intake of the animals Was estimated based on Water 
consumption and Was approximately 1400 mg/kg of body 
Weight, based upon an estimated consumption of 23 ml of 
Water per 100 g of body Weight, and an average body Weight 
of 25 g. This is equivalent to about 8.4 g/day for a 70 kg 
human. See Freireich, et al., Cancer Chemother. Rep. 50: 
219—244 (1966) incorporated by reference. For the third 
group, backs Were shaved, and the lauryl nicotinate ester 
Was applied to shaved areas, via 200 mg of lotion, containing 
10% (Wt/Wt) of the lauryl nicotinate ester. The amount of the 
ester applied is approximately 80—800 mg/kg, again assum 
ing an average Weight of 25 g. Using Freireich, supra, this 
is equivalent to a dose from about 0.48 to about 4.8 g/day/70 
kg human. The lotion Was applied daily for 13 Weeks. 
Leptin levels in plasma Were determined using a com 
mercially available murine leptin radioimmunoassay. The 
RIA Was carried out on fasting (16 h) blood samples 
obtained from the retroorbital plexus. The blood samples 
Were collected and centrifuged at 2000><g for 15 minutes to 
secure plasma. The results, summariZed in FIG. 3, shoW that 
oral niacin did increase the amount of circulating leptin, 
hoWever, the lauryl nicotinate ester surpassed it in terms of 
the amount of circulating leptin. 
EXAMPLE 3 
The experiments described in example 2 Were continued, 
in the experiment described in this example. Speci?cally, 
male BALB/C mice Were shaved, from the scapulae to tail 
bases. The subject animals then received topical application 
of the lauryl nicotinate ester lotion, described in example 2, 
supra, or myristyl nicotinate ester lotion, in varying concen 
trations. Controls received vehicle only. The lotion Was 
applied at a dose of 4 ml/kg/mouse. 
Serum leptin levels Were measured, as described, supra. 
The results indicate that the serum leptin levels increased by 
45% in the subject animals Which received the 10% lauryl 
nicotinate ester lotion, While the increase for subject animals 
Which received myristyl nicotinateesterWas 57% (for the 2% 
formulation), and 77% (for the 5% formulation). FIG. 4 
presents these results. 
EXAMPLE 4 
The association of leptin With Wound healing Was dis 
cussed supra. This correlation Was investigated in these 
experiments. 
Mice Were in?icted With full thickness Wounds of about 6 
mm in diameter, under anesthesia (sodium phenobarbital). 
They then received topical application of a 20% nicotinate 
ester lotion, every day, for 14 days. The dosing Was 100 pl 
US 6,750,234 B2 
5 
for each application, With tWo applications every day. As a 
control, the lotion Without the ester Was used. Wound 
diameter Was measured every day. 
The results are presented in FIG. 5, Which shoWs that the 
mice Which received the nicotinate ester containing formu 
lations shoWed a reduction of Wound thickness, as composed 
to controls. The lauryl ester Was most effective With a 43% 
reduction. 
When the serum leptin levels Were measured, the mice 
Which received the nicotinate ester application Were found to 
have an increase of 44% as compared to controls. These 
results are depicted in FIG. 6. 
The foregoing eXamples set forth various features of the 
invention Which include, inter alia, a method for stimulating 
production of leptin in a subject in need thereof, by admin 
istering to said subject a leptin stimulating amount of a 
nicotinic acid or nicotinic acid derivative, such as a nicotinic 
acid ester. Most preferably, this is a lauryl nicotinic acid 
ester, although other compounds, such as those described in 
the patent application cited supra may also be used. Espe 
cially preferred are nicotinic acid per se, or nicotinic acid 
alkyl esters, Where the ester moiety contains from 1—30, 
optionally substituted, carbon atoms. More preferably, the 
alkyl moiety contains 1—22 carbon atoms, most preferably 
1—18 carbon atoms. The subjects are preferably subjects 
suffering from a condition that can be alleviated by increased 
leptin levels, including those set forth in FIG. 1, improved 
immune function, skin epitheliation, hair follicle cycling, 
inhibition of tumor formation, such as skin tumor formation, 
and so forth. 
The mode by Which the nicotinic acid or ester is admin 
istered to the subject may vary. Oral, time release, 
intravenous, intradermal, and other forms of administration 
are contemplated, as topical administration. Such topical 
administration may be via a creme, lotion, liquid, aerosol, 
body Wash, mouthWash, toothpaste, gavage, or other form of 
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topical administration. For eXample, in the case of timed 
released application, “patches,” such as the type used in 
timed release of nicotine, bandages, Wraps, and so forth may 
be employed. 
The nicotinic acid ester is administered in an amount 
sufficient to stimulate leptin production. The dose used can 
and Will vary; hoWever, formulations should deliver, e.g., 
doses ranging from about 0.1 to about 10 g/day/70 kg body 
Weight, more preferably from about 0.1 to about 7 g/day/70 
kg body Weight, most preferably from about 0.4 to about 
5/g/day/70 kg body Weight. 
As indicated, supra, the stimulation of leptin production 
can lead, in addition to the effects associated With leptin 
previously, to regression of skin tumors, skin homeostases 
and remodeling, epidermal barrier development, Wound 
healing, and hair groWth. 
Other applications Will be clear to the skilled artisan and 
need not be elaborated herein. 
We claim: 
1. A method for increasing leptin levels in a subject 
suffering from a full thickness Wound comprising adminis 
tering to said subject an amount of a nicotinic acid alkyl 
ester sufficient to increase leptin levels in said subject so as 
to reduce thickness of said full thickness Wound, Wherein the 
alkyl chain of said nicotinic acid alkyl ester contains from 8 
to 22 carbon atoms. 
2. The method of claim 1, Wherein said alkyl chain 
contains 12 or 14 carbon atoms. 
3. The method of claim 1, Wherein said nicotinic acid 
alkyl ester is administered orally. 
4. The method of claim 1, Wherein said nicotinic acid 
alkyl eater is administered topically. 
5. The method of claim 1, comprising administering more 
than one nicotinic acid alkyl ester. 
